PlaqueTec
Develops AI-driven precision medicine tools aimed at improving assessment and management of cardiovascular disease by supporting personalized diagnosis and treatment decisions.
Overview
PlaqueTec develops AI-driven precision medicine solutions focused on cardiovascular disease, positioning its products to support more personalized assessment and management of cardiac conditions. The company emphasizes precision medicine for cardiovascular care and markets its technology to stakeholders involved in diagnosis and treatment of heart disease. PlaqueTec is an early-stage, Cambridge-based venture that completed an undisclosed financing of €4.2 million (reported as $5M total raised) on April 27, 2026 to advance its precision medicine work in cardiovascular disease.
Funding History
Cambridge’s PlaqueTec raises €4.2 million to advance precision medicine for cardiovascular disease
Frequently Asked Questions
- How much funding does AI Funding track for PlaqueTec?
- AI Funding tracks $5M for PlaqueTec across 1 funding round in this database.
- What does PlaqueTec do?
- PlaqueTec develops AI-driven precision medicine solutions focused on cardiovascular disease, positioning its products to support more personalized assessment and management of cardiac conditions. The company emphasizes precision medicine for cardiovascular care and markets its technology to stakeholders involved in diagnosis and treatment of heart disease. PlaqueTec is an early-stage, Cambridge-based venture that completed an undisclosed financing of €4.2 million (reported as $5M total raised) on April 27, 2026 to advance its precision medicine work in cardiovascular disease.
- Where is PlaqueTec headquartered?
- PlaqueTec is headquartered in Cambridge, United Kingdom.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.